Part 1 of our Cryo Cold Chain Management for CGT Series With a projected rate of 10-20 product approvals per year, the global cell and gene therapy (CGT) industry is rapidly evolving. The clinical pipeline delivers a promise to the patient population with unmet medical needs ranging from oncology to autoimmune diseases and rare genetic conditions. In […]
View Blog
Part 12 of our Bridging the Gap Series (Summary of the webinar session held in November 2024) Pictured in photo: Sickle cell warrior Jimi Olaghere climbed Mt. Kilimanjaro after receiving advanced gene therapy. The incredible potential of gene therapies like chimeric antigen receptor T-cell therapy (CAR-T) and clustered regularly interspaced short palindromic repeats (CRISPR) to cure genetic diseases […]
View Blog
Recap of 1 Year of our Bridging the Gap Series In November 2024, Azenta Life Sciences celebrated the one-year anniversary of its “Bridging the Gap” webinar series, an insightful resource in cell and gene therapy (CGT) education, co-sponsored by the Emily Whitehead Foundation. Over the past year, this series has become a resource for industry experts and […]
View Blog
Part 11 of our Bridging the Gap Series (Summary of the webinar session held in October 2024) In the rapidly advancing world of cell and gene therapy, we are witnessing groundbreaking innovations that have the potential to cure once-incurable diseases like cancer and sickle cell. Yet, as these transformative therapies emerge, a troubling reality persists: access to […]
View Blog
Part 10 of our Bridging the Gap Series (Summary of the webinar session held in September 2024) Access to life-saving cell and gene therapies is one of the most critical challenges facing healthcare today. While these therapies offer remarkable hope for patients battling life-threatening conditions like cancer and rare genetic diseases, the reality is that only a […]
View Blog
Part 9 of our Bridging the Gap Series (Summary of the webinar session held in August 2024) In the evolving landscape of cell and gene therapy, the manufacturing process is a crucial factor in ensuring that innovative treatments, such as CAR T-cell therapies, reach patients effectively. Autologous cell therapies, which involve modifying a patient’s own cells, present […]
View Blog
Imagine a scenario where a prominent life sciences company safeguards 573,000 biological samples collected two decades ago during a groundbreaking study. Today, these samples rest in a tucked-away basement of a modest laboratory, nestled among numerous cryogenic freezers within a section of the building inaccessible to anyone involved in the original research. The samples intermingle […]
View Blog
Part 8 of our Bridging the Gap Series (Summary of the webinar session held in July 2024) Imagine harnessing your body’s own immune cells to fight and destroy cancer—a reality that Tumor-Infiltrating Lymphocytes (TIL) therapy is making possible. TIL therapy was the key topic of our July “Bridging the Gap” webinar with guest speaker Raj Puri, M.D., […]
View Blog
Part 7 of our Bridging the Gap Series (Summary of the webinar session held in June 2024) What if you could transform the life of a child with leukemia by simply modifying their own cells? This is the promise of CAR T-cell therapy, a groundbreaking treatment that has already revolutionized cancer care. Yet, as Siddhartha Mukherjee, M.D., […]
View Blog
Part 6 of our Bridging the Gap Series (Summary of the webinar session held in May 2024) Welcome to another installment of the Bridging the Gap webinar series, your go-to place for the latest in cell and gene therapy. Presented by Azenta Life Sciences and the Emily Whitehead Foundation, this series is all about connecting the dots between […]
View Blog